Join us for a timely conversation with Verena Ross, Chair of the European Securities and Markets Authority (ESMA), as Europe advances its ambitious Savings and Investment Union agenda.

Life sciences companies are using AI to speed up drug discovery, accelerate commercialization timelines, and improve back-office functions. The strong AI market in the U.S. has allowed for collaborations between AI-focused tech companies, life sciences companies, and universities. However, limitations around centralized data availability have made for challenges with deploying technology for clinical and commercial purposes. Europe has unique advantages due to many countries having centralized health data stores, collaborative networks, and strong public funding for research. As we have seen increased investment for companies utilizing AI to improve patient outcomes, life sciences companies who can unlock cross-border collaborations in the AI space may have an edge to tap into capital markets.

Hosted by Benett Jones | Canada continues to attract significant domestic and international capital across a broad range of asset classes. This session will explore the evolving investment landscape, highlighting opportunities across traditional and next-generation infrastructure, energy and resource development projects that are shaping North American and global economic futures.